HER2+ Breast Cancer

Dr. Clifton and Dr. Gandhi discuss the critical role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer, and its impact on prognosis and treatment decision-making.

Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.

Alberto Montero, MD, MBA, CPHQ, discusses data with the combination of zanidatamab and evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.

Polly Niravath, MD, discusses a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab in HER2-enriched early breast cancer.

Junjie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

T-DXd displayed favorable HRQOL and neurological function results in HER2+ metastatic breast cancer regardless of the presence of brain metastases.

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

DETECT V trial data suggest dual HER2-targeted and endocrine therapy might be an effective option in HER2+/HR+ breast cancer.

Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

David Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.

Kevin Kalinsky, MD, MS, discusses the phase 3 DESTINY-Breast06 trial evaluating trastuzumab deruxtecan in HER2-expressing breast cancer.

Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.

Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.

David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.

Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.

IBI354 showed favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.

Sheldon M. Feldman, MD, discusses the recognition of racial disparities in breast cancer, as well as the mitigation of treatment-related toxicities.

Neoadjuvant SHR-A1811 plus pyrotinib generated response and had a manageable safety profile in HER2+ breast cancer.

Sung Gwe Ahn, MD, PhD, discusses survival outcomes with ovarian function suppression-based endocrine therapy based on the HERA trial in HR-positive, HER2-positive breast cancer.

David Rimm, MD, discusses the current limitations of immunohistochemistry diagnostic kits for HER2-low and HER2-ultralow breast cancer.

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.